Puerto Vallarta - Beaches, Hotels, Villa Rentals, Resorts

BioTime, Inc. Announces Plan to Map the Human Embryome

EMERYVILLE, Calif. (Business Wire EON) December 18, 2007 -- "Human embryonic stem cells have enormous potential in medicine due to their ability to become all of the cell types of the human body," said Michael West, Ph.D., Chief Executive Officer of BioTime. "A careful delineation of markers of embryonic cell pathways will create a map of the embryome that will facilitate the purification of many therapeutically-useful cell types. The identification of specific therapeutic cell lines will, in turn, help ensure that future cell-based therapies are safe and unlikely to suffer serious side effects, such as tumor formation."

The relational database will be built using core software licensed, on an exclusive basis for this purpose, from Targeted Therapeutics Consulting, Inc., which currently operates a relational database for cancer therapy research and the development of anti-cancer drugs. When the new embryome database is operational, Embryome Sciences will provide researchers access to it through an internet website. Embryome Sciences plans to launch this new website early next year beginning with a database map of the embryome of the mouse, and plans to add the human embryome by June 2008.

In addition to providing access to its embryome database, Embryome Sciences' new website may also be used to market stem cell research products developed by Embryome Sciences and by other companies.

Other products that Embryome Sciences plans to develop include growth and differentiation factors that can be used to induce embryonic stem cells to become desired cell types, and a line of purification tools useful to researchers in purification and quality control analysis of products in regenerative medicine.

BioTime believes that the development of products such as these in the Embryomics(TM) sector may allow Embryome Sciences to commercialize products more quickly, using less capital, than developing therapeutic products from stem cells. Embryome Sciences' plan is to market its products and services to companies and academic researchers, such as those working under the $3 billion California stem cell initiative, in this growing industry, and to provide them the tools they need to attain their goals.

About BioTime, Inc.

BioTime, headquartered in Emeryville, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ Corp. under exclusive licensing agreements. BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it plans to develop new medical and research products using embryonic stem cell technology. Information about BioTime can be found on the web at www.biotimeinc.com. Hextend(R), PentaLyte(R), HetaCool(R), and Embryomics(TM) are trademarks of BioTime, Inc.

About Targeted Therapeutics Consulting, Inc.

Targeted Therapeutics Consulting (TTC), a Mill Valley, California-based company, has created a unique information platform and project management tool for cancer drug development professionals in industry and academia. Subscription to TTC's proprietary database provides access to comprehensive information relevant to drug development in oncology and related information on tumor biology. TTC utilizes its web-based information technology to provide individualized consulting solutions. TTC also provides partner companies with relational database solutions for capturing and analyzing biological and clinical trial data. TTC will continue expanding its services to other areas of medicine. Information about TTC is available on the web at www.targetedtherapeutics.com or by phone at (415) 388-5954.

Forward Looking Statements

The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the success of BioTime in developing new stem cell products and technologies; results of clinical trials of BioTime products; the ability of BioTime and its licensees to obtain additional FDA and foreign regulatory approval to market BioTime products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime products, and the ability of BioTime to raise the capital needed to finance its current and planned operations. Other factors that could affect BioTime's operations and financial condition are discussed in BioTime's Annual Report on Form 10-KSB filed with the Securities and Exchange Commission.

Click here to join our email alert list.. (OTCBB:BTIM) announced its plan to build a relational database for its Embryome Sciences subsidiary that will display information useful in identifying the hundreds of cell types that can be made from human and mouse embryonic stem cells. BioTime believes that this database will be the first of its kind in the stem cell field.

"Human embryonic stem cells have enormous potential in medicine due to their ability to become all of the cell types of the human body," said Michael West, Ph.D., Chief Executive Officer of BioTime. "A careful delineation of markers of embryonic cell pathways will create a map of the embryome that will facilitate the purification of many therapeutically-useful cell types. The identification of specific therapeutic cell lines will, in turn, help ensure that future cell-based therapies are safe and unlikely to suffer serious side effects, such as tumor formation."

The relational database will be built using core software licensed, on an exclusive basis for this purpose, from Targeted Therapeutics Consulting, Inc., which currently operates a relational database for cancer therapy research and the development of anti-cancer drugs. When the new embryome database is operational, Embryome Sciences will provide researchers access to it through an internet website. Embryome Sciences plans to launch this new website early next year beginning with a database map of the embryome of the mouse, and plans to add the human embryome by June 2008.

In addition to providing access to its embryome database, Embryome Sciences' new website may also be used to market stem cell research products developed by Embryome Sciences and by other companies.

Other products that Embryome Sciences plans to develop include growth and differentiation factors that can be used to induce embryonic stem cells to become desired cell types, and a line of purification tools useful to researchers in purification and quality control analysis of products in regenerative medicine.

BioTime believes that the development of products such as these in the Embryomics(TM) sector may allow Embryome Sciences to commercialize products more quickly, using less capital, than developing therapeutic products from stem cells. Embryome Sciences' plan is to market its products and services to companies and academic researchers, such as those working under the $3 billion California stem cell initiative, in this growing industry, and to provide them the tools they need to attain their goals.

About BioTime, Inc.

BioTime, headquartered in Emeryville, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ Corp. under exclusive licensing agreements. BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it plans to develop new medical and research products using embryonic stem cell technology. Information about BioTime can be found on the web at www.biotimeinc.com. Hextend(R), PentaLyte(R), HetaCool(R), and Embryomics(TM) are trademarks of BioTime, Inc.

About Targeted Therapeutics Consulting, Inc.

Targeted Therapeutics Consulting (TTC), a Mill Valley, California-based company, has created a unique information platform and project management tool for cancer drug development professionals in industry and academia. Subscription to TTC's proprietary database provides access to comprehensive information relevant to drug development in oncology and related information on tumor biology. TTC utilizes its web-based information technology to provide individualized consulting solutions. TTC also provides partner companies with relational database solutions for capturing and analyzing biological and clinical trial data. TTC will continue expanding its services to other areas of medicine. Information about TTC is available on the web at www.targetedtherapeutics.com or by phone at (415) 388-5954.

Forward Looking Statements

The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the success of BioTime in developing new stem cell products and technologies; results of clinical trials of BioTime products; the ability of BioTime and its licensees to obtain additional FDA and foreign regulatory approval to market BioTime products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime products, and the ability of BioTime to raise the capital needed to finance its current and planned operations. Other factors that could affect BioTime's operations and financial condition are discussed in BioTime's Annual Report on Form 10-KSB filed with the Securities and Exchange Commission.

Click here to join our email alert list.

MORE ARTICLES:

Honeymoon Vacation Ideas can be Economical
If you are looking for honeymoon vacation ideas that will be the most enjoyable without putting you into massive debt, consider some of these tips.The purpose of the honeymoon vacation is only minimally to live for a few days like extravagant royalty.

Auto Loans Fast Approval  get the Car as soon as Possible
Introduction

International Travel Accessory Tip: 4 Must Have Travel Accessories
Whether you are traveling for business or vacation, you want to be able to relax and enjoy the trip and even take in some sights. When it comes time to do the packing for your trip, there?s always the question of what do I need?

Ybor "Rum" City, Tampa, Florida USA Plays Host to the 2nd Annual International Cane Spirits Festival & Tasting Competition
Tampa's Ybor City again plays host to the 2nd Annual International Cane Spirits Festival & Tasting Competition (ICS) on Saturday night, March 24, 2007

BuyingAdvice.com Survey Reveals Car Buyers Paying Closer Attention to Gas Mileage
Fuel consumption is becoming more and more important for new car buyers, according to an exclusive survey by BuyingAdvice.com (http://www.buyingadvice.com/).

Holiday in the Rias Baixas
Galicia in particular and Northern Spain in general have long been considered to be a hidden jewel in the entire Spanish tourist industry and hidden away within Galicia itself are some further jewels and we are going to examine Costa da Morte further.

San Diego's Keating Hotel Wins the Earth-Minded Awards by Hospitality Design Magazine
The Keating Hotel, San Diego's premier boutique hotel, was named the winner of the inaugural Earth-Minded Awards (EMA), presented by Hospitality Design (HD) magazine and American Society of Interior Designers (ASID).

Hotel in Pittsburgh, PA Celebrates 20 Years of Bringing Families Together
Pittsburgh Airport Marriott Presents the 20th Annual Easter Bunny Ballroom Brunch

Historic Dearborn Michigan Hotel, The Dearborn Inn, Completing $5.5 Million Renovation
Hotel in Dearborn MI, commissioned by Henry Ford in 1931, refurbished with regional flair.

Presenting: A Behind-the-scenes Look At The Historic Royal York Hotel - One Of Toronto's Crown Jewels (part Ii)
In 1999, Canadian Pacific Hotels & Resorts acquired Fairmont Hotels to form Fairmont Hotels and Resorts, a global company with a portfolio of unique architecturally interesting luxury hotels throughout North America and the Caribbean. The official name of the hotel since then has been the Fairmont Royal York. In the early years of the New Millennium Fairmont invested almost $15 million in transforming the new lobby area, public meeting areas, the Epic Restaurant as well as the Imperial Room and Library Bar. Following the history displays on the Mezzanine Level I got to see the Concert Hall which housed the first production of the Canadian Opera Company. This grand space featured a projection booth as it was also used as a cinema. The ori...

Le Meridien Khao Lak Beach & Spa Resort Hotel
As you begin to read through this informative article, give each point a chance to sink in before you move on to the next.

Cape Town – A Look at Africa's Most Beautiful City
As winter approaches in the northern hemisphere, summer beckons in the south. This is the time to take a few days off and follow the sun! The best place to catch the sun in the end of year holiday season is without doubt Cape Town.

Ricky Nelson Remembered Tour Coming to the Boardwalk -- Matthew and Gunnar Nelson To Headline at Atlantic City Hilton
The Nelson Brothers announce The Ricky Nelson Remembered Tour starring Matthew & Gunnar Nelson and The Stone Canyon Band will be coming to the famed Boardwalk for six shows June 1-5, 2008 to the Atlantic City Hilton.

The Uniqueness of the Litigation Process in Cruise Ship Injuries
Taking a vacation by way of a cruise is such a great opportunity and adventure for anyone. However, much as you try to prevent accidents and other such unexpected incidents, what can you do when you suffered from injuries and other damages while on a cruise ship?